Please provide your email address to receive an email when new articles are posted on . Results of a 24-week trial that compared biosimilar epoetin alfa-epbx and epoetin alfa in patients on ...
Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network Patients (N = 301) with ...
Purpose: The cost of darbepoetin alfa versus that of epoetin alfa in a hospital setting was studied. Methods: The study was an observational, retrospective review of the hospitalwide use of ...
Epoetin-β is used to treat patients with cancer undergoing chemotherapy to alleviate the symptoms of anaemia, reduce the risk of blood transfusions and improve quality of life (QoL). Data presented in ...
Subcutaneous epoetin beta is a convenient and effective treatment for anemia in peritoneal dialysis patients. Less frequent dosing could enhance ease of use, but the effect on efficacy has not been ...
The FDA has approved Pfizer’s epoetin alfa-epbx (Retacrit), a biosimilar to epoetin alfa (Epogen), marking the first biosimilar approval of 2018 and the first biosimilar erythropoiesis-stimulating ...
November 6 (Istanbul) — Cancer patients receiving epoetin to prevent anemia during chemotherapy or radiation treatment fared just as well on once-weekly doses as on the traditional thrice-weekly ...
Please provide your email address to receive an email when new articles are posted on . Hospira Inc. presented two studies that demonstrate the pharmacokinetic and pharmacodynamic equivalence of its ...
Value of caregiver ratings in evaluating the quality of life of patients with cancer. More than 500 community-based oncologists enrolled 2,342 patients with malignancies undergoing cytotoxic ...
SAN FRANCISCO--(BUSINESS WIRE)--Dosis, a market leader in artificial intelligence-powered precision dosing, announced today the publication of two abstracts to be showcased at the American Society of ...
In patients with high-risk breast cancer, addition of the erythropoiesis-stimulating agent (ESA) epoetin alfa to the chemotherapy regimen may help avoid the decrease in hemoglobin levels and resulting ...
Editor's Note: The post by Dennis Cotter below addresses the way in which Medicare should incorporate erythropoiesis-stimulating agents (epoetin) into its composite-rate payment for end-stage renal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results